Accordingly, the combination of CD36 and FASN inhibitors significantly reduced PCa proliferation in vivo and in patient-derived PCa explants and it increased sensitivity to ionizing radiation, suggesting a potential synergistic effect in the clinical setting (65–68). The gene discussed is FASN; the disease is posterior cortical atrophy.